Related Experiment Video
Updated: Aug 5, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Sympathetic β2-adrenergic receptor blockade overcomes docetaxel resistance in prostate cancer
Mi Zhang1, Fangfang Chen1, Xueqing Sun2
1Institution of Life Science, Chongqing Medical University, Chongqing, China.
Purpose:
Due to the limited effective therapies, resistance to docetaxel is ordinarily fatal and remains a critical clinical challenge.β2-adrenergic receptor(β2-AR)can promote the metastasis and invasion of prostate cancer, but the role in chemotherapy-resistant prostate cancer remains unclear.
Methods:
By downloading the GEO database in NCBI, the expression of β2-AR in different prostate tissues was analyzed. We constructed docetaxel-resistant prostate cancer cell lines by the method of dose-escalation. LC3B-labeled stable cells and shAtg5 knockdown stable cells were constructed by lentivirus infection. The molecular mechanism of β2-AR affecting docetaxel sensitivity through apoptosis and autophage were investigated by flow cytometry, mitochondrial membrane potential and western blot. Then we detected the interaction between autophagy and apoptotic by performing immunoprecipitation assay.
Results:
We show that restraining the activity of β2-AR sensitized the cell response and reduced the resistance to docetaxel. The mechanism involves the regulation of β2-AR in the cellular response to docetaxel through apoptosis and autophagy via caspase signaling and Atg5/AMPK/mTOR pathway as well as the effect of β2-AR on the crosstalk between apoptosis and autophagy via p38 MAPK and JNK/c-Jun/FOXO3a signaling pathways.
Conclusion:
Our data demonstrate that β2-AR inhibitor-induced autophagy and apoptosis contribute to the effectiveness responses to docetaxel in castration-resistant prostate cancer, and in combination with pharmacological agents of β2-AR and autophagy inhibitors may provide a potential therapeutic strategy to enhance the limited capacity of docetaxel to control castration-resistant prostate cancer.
Insights
Targeting the beta-2 adrenergic receptor (β2-AR) enhances docetaxel effectiveness in resistant prostate cancer by promoting apoptosis and autophagy. This suggests β2-AR inhibitors could improve chemotherapy outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Docetaxel resistance in prostate cancer is a major clinical challenge with limited therapeutic options.
- The role of the beta-2 adrenergic receptor (β2-AR) in chemotherapy resistance, particularly docetaxel resistance, remains poorly understood.
Purpose of the Study:
- To investigate the role of β2-AR in docetaxel-resistant prostate cancer.
- To elucidate the molecular mechanisms by which β2-AR influences docetaxel sensitivity, focusing on apoptosis and autophagy.
Main Methods:
- Analyzed β2-AR expression in prostate tissues using GEO database.
- Developed docetaxel-resistant prostate cancer cell lines via dose-escalation.
- Investigated the impact of β2-AR on docetaxel sensitivity using flow cytometry, western blot, and immunoprecipitation assays.
- Examined the interplay between apoptosis and autophagy pathways.
Main Results:
- Restraining β2-AR activity sensitized prostate cancer cells to docetaxel, reducing resistance.
- β2-AR regulates docetaxel response through apoptosis (caspase signaling) and autophagy (Atg5/AMPK/mTOR pathway).
- β2-AR influences the crosstalk between apoptosis and autophagy via p38 MAPK and JNK/c-Jun/FOXO3a signaling.
Conclusions:
- Inhibiting β2-AR induces autophagy and apoptosis, enhancing docetaxel efficacy in castration-resistant prostate cancer.
- Combination therapy with β2-AR inhibitors and autophagy inhibitors presents a potential strategy to overcome docetaxel resistance.
More Related Videos
Related Concept Videos
Treatment Resistant Cancers
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Desensitization and Tachyphylaxis
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Drugs that Stabilize Microtubules

